Numis Securities reissued their hold rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report issued on Wednesday morning. They currently have a GBX 1,730 ($22.61) target price on the stock.

Several other research firms also recently weighed in on HIK. Barclays reiterated an equal weight rating on shares of Hikma Pharmaceuticals in a report on Wednesday, December 19th. Jefferies Financial Group upgraded shares of Hikma Pharmaceuticals to a buy rating and lifted their target price for the company from GBX 1,643 ($21.47) to GBX 2,000 ($26.13) in a report on Tuesday, November 27th. Peel Hunt reiterated a hold rating on shares of Hikma Pharmaceuticals in a report on Thursday, December 6th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,050 ($13.72) to GBX 1,900 ($24.83) and gave the company a neutral rating in a report on Tuesday, November 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of GBX 1,835.71 ($23.99).

HIK stock opened at GBX 1,598.50 ($20.89) on Wednesday. Hikma Pharmaceuticals has a one year low of GBX 844.40 ($11.03) and a one year high of GBX 2,089 ($27.30). The company has a debt-to-equity ratio of 46.76, a quick ratio of 1.11 and a current ratio of 1.90. The company has a market cap of $3.86 billion and a PE ratio of -4.77.

The business also recently announced a dividend, which will be paid on Wednesday, May 22nd. Investors of record on Thursday, April 4th will be issued a $0.26 dividend. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, April 4th. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.12. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is -0.06%.

In other Hikma Pharmaceuticals news, insider Mazen Darwazah purchased 20,000 shares of the company’s stock in a transaction on Wednesday, March 13th. The stock was acquired at an average price of GBX 1,582 ($20.67) per share, for a total transaction of £316,400 ($413,432.64). Also, insider Mary (Nina) Henderson purchased 2,000 shares of the company’s stock in a transaction on Friday, March 15th. The stock was acquired at an average price of GBX 1,563 ($20.42) per share, with a total value of £31,260 ($40,846.73).

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Featured Article: What is a Futures Contract?

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.